作为广泛存在于MM细胞表面的生物标志物,靶向BCMA的疗法研发热度极高,Blenrep的先行者优势本就不多,放在现在的市场环境里更是平平无奇。 多款BCMA CAR-T上市,出色的响应率和疗效在临床上的诱惑,让高昂的开销都没那么让人望而却步;强生的BCMA/...
另一边Tecvayli采用的虽然也是高亲和力CD3,但其结合动力学大概率经过调整,且构建于IgG骨架(150 kD),有利于对T细胞的激活效果进行优化,从而实现临床上安全、有效的表现,和一周一次的给药频率。同时,近年研究发现,亦可以通过降低CD3的亲和力,特异地激活T...
CD3-engaging bispecific antibodies (bsAbs) and chimeric antigen receptor (CAR) T cells are potent therapeutic approaches for redirecting patient T cells to recognize and kill tumors. Here we describe a fully human bsAb (REGN5458) that binds to B-cell maturation antigen (BCMA) and CD3, and co...
2a). We modified the CD3+ T cells from healthy donors’ peripheral blood mononuclear cells (PBMCs)31. The transduction efficacy of CAR-T cells was detected by flow cytometry. The transduction efficacy of CD24-CAR-T cells was 43% (Supplementary Fig. 5a). CD34-positive CAR-T cells were ...
Teclistamab, a bispecific antibody that targets both BCMA and CD3 (accelerated approval; full approval pending) and results from the phase 1/2 MajesTEC-1 study, showed an ORR of 63% and mDOR of 18.4 months11,12. Ide-cel and cilta-cel are autologous CAR T cell therapies targeting B...
The cells were transduced with recombinant lentiviral verctors which respectively contained the anti-BCMA or anti-CD19 single chain variable fragment (scFv), the cytoplasmic portion of the OX40 and CD28 costimulatory moiety, and the CD3z T-cell activation domain. This is the new third ...
BMS-986354 contains the same CAR construct present in orva-cel, with an anti-BCMA domain, a CD8 transmembrane domain, 4-1BB costimulatory domain and CD3-z signaling domain [10], but BMS-986354 is manufactured using the proprietary NEX-T® process. The manufacturing process involves selection...
Remarkably, the CD28TM.CD28IC-based anti-BCMA construct showed better proliferative capacity (p < 0.05) of all CD3 + T cells (33 ± 16) and CAR T cells (71 ± 34) compared to 41BBIC-based T cells (< 10) and CAR T cells (< 12) (Fig. 5A). No ...
(BCMA) are disclosed. Binding sites from humanized anti-CD3 and anti-BCMA antibodies are incorporated into a Fabs-in-Tandem Immunoglobulin format without significant loss of binding affinity, and the resultant bispecific, multivalent binding proteins are able to bind to both CD3 and BCMA ...
As shown in (A) of FIG. 4, the binding of BCMA×CD3 bispecific antibody PRO03178 to human BCMA on HEK293T/huBCMA cells was stronger than that of positive control 2. Specifically, the EC50 of the binding curve of antibody PRO03178 was about 5 times lower than that of positive control...